BLACKSBURG, VA – In a good day for life sciences funding news, we see via a regulatory filing that investors have pumped another $25 million into Intrexon, a company focused on modular DNA control systems for biotherapeutics and other industry sectors. Intrexon just raised $10 million in June and previously raised $25 million in 2007.
The company disclosed the funding in a filing with the U.S. Securities and Exchange Commission. New River Management funds, managed by Third Security and NewVa Capital Partners have been the company’s primary investors.
Intrexon says its modular DNA control systems can enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial enzymes and agbio.
Its most advanced immunomodulatory therapy is intended to control and enhance the immune-modulating performance of dendritic cells to treat solid tumor cancers.
It is also using its “UltraVector” system of modular DNA controls to enhance human protein production for therapeutic drugs.
It saysits capabilities also represent “an unparalleled opportunity to develop protein production systems that can be embedded inside a patient’s body and then regulated through the dosing of our external small molecule activator.”
In September, the company bought the assets and operations of Avalon Pharmaceutical Inc., a subsidiary of Clinical Data Inc., and assumed the lease on its Germantown, MD bioassay facility.
The company’s headquarters is located at the Virginia Tech Corporate Research Center in Blacksburg, Virginia, which is also the primary site for its advanced transgene engineering operations. Intrexon has additional business and R&D operations located in Germantown, MD; San Francisco, CA; and Valley Forge, PA. — By Allan Maurer
Online: www.dna.com
Join hundreds of Marketing Professionals and Internet Execs at Atlanta’s premier Digital event – Digital Summit 2012
www.digitalsummit.com
Related Stories:
- Blacksburg-based Intrexon gets $37.5M financing shot in the arm
- Intrexon on a roll, grabs another $17.4M financing
- Intrexon adds $10M C-2 round for DNA control systems
- Intrexon rakes in $25M round for biotherapeutic control systems
- Virginia’s Intrexon Corp. closes $25 million financing
© 2010, TechJournal. All rights reserved.
[...] http://www.techjournalsouth.com/2010/01/intrexon-grabs-25m-for/ [...]
[...] raised the $25 million from two investors in December 2009, according to an SEC filing, which we reported here in [...]